Literature DB >> 20435464

Clinical evaluation of an immbolization system for stereotactic body radiotherapy using helical tomotherapy.

Alonso N Gutiérrez1, Sotirios Stathakis, Richard Crownover, Carlos Esquivel, Chengyu Shi, Niko Papanikolaou.   

Abstract

In this study, a clinical evaluation of the Body Pro-Lok™ System combined with the TomoTherapy megavoltage computed tomography (MVCT) was performed for lung and liver stereotactic body radiotherapy (SBRT) to reduce interfractional setup uncertainty. Twenty patients treated with 3-5 fractions of SBRT were analyzed retrospectively. The Body Pro-Lok™ system was used in both CT simulation and during patient treatment setup. Patients were immobilized with a vacuum cushion placed posteriorly over the thoracic region, an abdominal compression plate, and a knee and foot sponge. Pretreatment MVCT scans of the TomoTherapy HI-ART II unit were fused with the planning kVCT before delivery of each fraction to determine the interfractional setup error. A total of 84 shifts were analyzed to assess the interfractional setup accuracy. Results showed that the mean interfractional setup errors and standard deviations were -0.9 ± 3.1 mm, 1.2 ± 5.5 mm, and 6.5 ± 2.6 mm for lateral (IEC-X), longitudinal (IEC-Y), and vertical (IEC-Z) variations, respectively. The maximum motion was 17.1 mm in the longitudinal direction. When all 3 translational coordinates were analyzed, a mean composite displacement vector of 8.2 ± 2.0 mm (range 4.1-11.7 mm) was obtained for all patients. Based on the findings, image-guided SBRT using the Body Pro-Lok™ system in conjunction with the MVCT of TomoTherapy is capable of minimizing interfractional setup error and improving treatment accuracy.
Copyright © 2011 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20435464     DOI: 10.1016/j.meddos.2010.02.003

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  7 in total

1.  Stereotactic ablative body radiotherapy for non-small-cell lung cancer: setup reproducibility with novel arms-down immobilization.

Authors:  Karen Moore; Claire Paterson; Jonathan Hicks; Stephen Harrow; Mark McJury
Journal:  Br J Radiol       Date:  2016-10-06       Impact factor: 3.039

2.  Dosimetric quantification of dose fall-off in liver SBRT planning using dual photon energy IMRT.

Authors:  J Henry; C Moreno; R L Crownover; D Baacke; N Papanikolaou; A N Gutierrez
Journal:  J Radiosurg SBRT       Date:  2016

3.  Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; James S Welsh; Si Young Jang; Carol Howe; Ritsuko Komaki
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

4.  A randomised comparison of three different immobilisation devices for thoracic and abdominal cancers.

Authors:  Catherine Hubie; Maddison Shaw; Sean Bydder; Jonny Lane; Gemma Waters; Megan McNabb; Rachel Kearvell; Alicia Concannon; Chrianna Bharat; Rob Appleyard
Journal:  J Med Radiat Sci       Date:  2016-12-20

5.  Evaluation of initial setup errors of two immobilization devices for lung stereotactic body radiation therapy (SBRT).

Authors:  Yoshihiro Ueda; Teruki Teshima; Higinia Cárdenes; Indra J Das
Journal:  J Appl Clin Med Phys       Date:  2017-05-14       Impact factor: 2.102

6.  Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.

Authors:  Alexander Chi; Pan Ma; Guishan Fu; Gerry Hobbs; James S Welsh; Nam P Nguyen; Si Young Jang; Jinrong Dai; Jing Jin; Ritsuko Komaki
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  Use of surface-guided radiation therapy in combination with IGRT for setup and intrafraction motion monitoring during stereotactic body radiation therapy treatments of the lung and abdomen.

Authors:  John H Heinzerling; Carnell J Hampton; Myra Robinson; Megan Bright; Benjamin J Moeller; Justin Ruiz; Roshan Prabhu; Stuart H Burri; Ryan D Foster
Journal:  J Appl Clin Med Phys       Date:  2020-03-20       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.